Lipid modulation and atherosclerotic events: Extending the clinical spectrum with fibrates and statins Evan A. Stein Clinical Trials Review Pages: 11 - 13
Does differing metabolism by cytochrome P450 have clinical importance? Michael H. Davidson OriginalPaper Pages: 14 - 19
Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins? Agostino FaggiottoRodolfo Paoletti OriginalPaper Pages: 20 - 25
Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk MacRae F. LintonSergio Fazio OriginalPaper Pages: 29 - 35
Mechanism of action of niacin on lipoprotein metabolism Vaijinath S. KamannaMoti L. Kashyap OriginalPaper Pages: 36 - 46
Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol Patrick H. BowenJohn R. Guyton OriginalPaper Pages: 58 - 63
Niacin dosing: Relationship to benefits and adverse effects David M. CapuzziJohn M. MorganCharles M. Intenzo OriginalPaper Pages: 64 - 71
Complete and selective estrogenic effects on lipids and cardiovascular disease Stefania Lamon-Fava OriginalPaper Pages: 72 - 75
Lipophilic calcium antagonists in antiatherosclerotic therapy Stefano BellostaFranco Bernini OriginalPaper Pages: 76 - 81